Physician profile
Michael N Daniels
NPI 1356634497
$3,771.55
in general payments reported to CMS, 2019-2025
33 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $487 · 2020: $477 · 2021: $443 · 2022: $579 · 2023: $574 · 2024: $754 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,766 · Education: $19.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,765.91 |
| Education | $19.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $500.60 | 2019-2024 | Farxiga, Lokelma |
| Amgen INC. | $417.43 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Vifor Pharma, INC. | $279.34 | 2019-2025 | Veltassa |
| Travere Therapeutics, INC. | $254.34 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $231.24 | 2019-2024 | Jynarque |
| Akebia Therapeutics INC | $213.43 | 2019-2025 | Vafseo |
| Alexion Pharmaceuticals, INC. | $184.99 | 2019-2023 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $149.17 | 2022-2025 | Acthar, Terlivaz |
| Glaxosmithkline, LLC. | $142.99 | 2021-2024 | Benlysta, Jesduvroq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $135.02 | 2019-2025 | |
| Fresenius USA Marketing, INC. | $127.01 | 2019-2024 | Velphoro |
| Opko Pharmaceuticals, LLC | $126.19 | 2021-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $118.02 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.82 | 2020-2024 | Gattex |
| Calliditas Therapeutics US INC. | $95.26 | 2023-2025 | Tarpeyo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $85.51 | 2021-2024 | Crysvita, Crysvita |
| Novartis Pharmaceuticals Corporation | $75.80 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $66.61 | 2021-2022 | |
| Baxter Healthcare | $63.77 | 2022-2024 | Renal - Chronic |
| Medtronic, INC. | $56.25 | 2022-2024 | |
| Kyowa Kirin, INC. | $55.65 | 2024 | Crysvita |
| Ani Pharmaceuticals, INC. | $47.65 | 2022-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $42.83 | 2024 | Jardiance |
| Biomerieux INC | $42.00 | 2023 | |
| Tactile Systems Technology INC | $20.83 | 2020 | |
| Amag Pharmaceuticals, INC. | $20.61 | 2020 | |
| Horizon Therapeutics Plc | $20.06 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.86 | 2023 | Jardiance |
| Novo Nordisk INC | $19.43 | 2025 | Ozempic |
| Ardelyx, INC. | $19.09 | 2023 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $17.29 | 2023 | Oxlumo |
| Janssen Pharmaceuticals, INC | $15.15 | 2020 | |
| Avion Pharmaceuticals | $12.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Daniels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.